# Screen every cancer patient for financial toxicity as a vital sign, with navigation

Source: https://onco.cc/ideas/idea-reg-financial-toxicity-vital-sign/  
OnCo record `idea-reg-financial-toxicity-vital-sign` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cancer costs push patients into debt and make them skip treatment. Asking about money at every visit, and having someone to help, catches this before it does harm.

## Summary

Financial toxicity affects a large share of patients even in insured and universal systems and is associated with non-adherence and worse survival. Validated instruments (COST-FACIT) exist, and financial navigation programmes have shown reductions in patient debt and distress in US trials. The proposal is to embed a short financial toxicity screen in routine patient-reported outcome collection at each cycle, with an automatic referral to a financial navigator and a data feed to payers documenting the burden by drug and regimen.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Routine screening with navigation reduces the proportion of patients reporting severe financial toxicity by a third, reduces treatment non-adherence for oral oncolytics, and generates drug-level financial burden data that payers use in negotiations.
- Rationale: Financial toxicity is a recognised adverse effect that is not measured, so it is not managed; the same logic that made pain a vital sign applies, and navigation interventions have randomised evidence of benefit.
- Proposed test: Cluster-randomised trial across 20 cancer centres of routine screening plus navigation versus usual care with financial toxicity score, adherence and out-of-pocket cost at 12 months.
- Maturity: early-clinical
- Actor: clinic

## Sources

- Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017): https://doi.org/10.1038/nrclinonc.2017.31

## Connected records

- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- key papers: [The high price of anticancer drugs: origins, implications, barriers, solutions](https://onco.cc/key-papers/paper-prasad-nat-rev-clin-oncol/)
- technologies: [Money after treatment: what the cost of cancer does once the treatment has finished](https://onco.cc/technologies/rejuv-life-money-after-treatment/), [Screening for distress: what the thermometer can and cannot do](https://onco.cc/technologies/rejuv-mind-distress-screening/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/), [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-financial-toxicity-vital-sign.json